Reading the tape
NYSE: USNA
USANA Health Sciences, Inc.
Consumer Defensive · Packaged Foods
Market Cap
$342.56M
52w High
$38.32
52w Low
$16.60
P/E
31.57
Volume
73.56K
Outstanding Shares
18.46M
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -35.85%Revenue (TTM): 8.28%FCF (TTM): -83.26%P/FCF: 98th pct
What changed
The stock fell 35.85% over the last year. Revenue grew 8.28% over the trailing twelve months. Operating margin moved from 7.76% to 5.5%. Free cash flow declined 83.26% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 5.5%. A decisive move in revenue — currently up 8.28% — would be the clearest signal to resolve the ambiguity.
Company profile
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products.
CEOKevin G. Guest
SectorConsumer Defensive
IndustryPackaged Foods
Employees1,700
IPO dateApr 4, 1994
Valuation
Forward P/E—
EV/EBITDA2.39
Enterprise value$216.7M
Stock splits
Nov 23, 2016↑ Forward
Every 1 shares became 2
Oct 31, 2003↑ Forward
Every 1 shares became 2
Aug 4, 1998↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth5.89%
Gross margin78.29%▼1.44%vs FY2024
Operating margin5.5%▼29.18%vs FY2024
ROE2.02%▼74.45%vs FY2024
Analyst consensus
RatingHold
Target price$35.00▲88.58%
2
Buy
5
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est $0.44 · Revenue est $240.99M
View